Understanding T cell responses to COVID-19 vaccines in patients with X-linked Agammaglobulinemia
Official title: Vaccine-induced SARS-CoV-2-specific T cell responses in patients with X-linked Agammaglobulinemia
Funded at Univ of North Carolina Chapel Hill · NIH-10762476 · Data updated 2026-11-12
This study is looking at how well people with X-linked Agammaglobulinemia (XLA) respond to COVID-19 vaccines, especially focusing on their T cell responses, to see if the vaccines can still help their immune system fight the virus even though they can't make antibodies.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | January 9, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $195,770 |
| NIH project number | 5R21AI168980-02 |
| Project ID | NIH-10762476 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with X-linked Agammaglobulinemia who are at least 21 years old.
✕Less likely to help
Patients without primary immune deficiencies or those who do not have X-linked Agammaglobulinemia may not benefit from this research.
What this research studies
This research investigates how patients with X-linked Agammaglobulinemia (XLA), a primary immune deficiency, respond to SARS-CoV-2 vaccines, particularly focusing on T cell responses. Since XLA patients cannot produce antibodies due to their condition, the study aims to determine if the vaccines can still elicit effective T cell responses that may help control the virus. The research will involve monitoring these patients after vaccination to assess their immune responses and gather data that could inform future vaccination guidelines for individuals with similar immune deficiencies.
Why it matters
Potential benefit: If successful, this research could provide critical insights into how to protect patients with XLA from COVID-19 through vaccination strategies.
How similar studies have gone: While research on T cell responses in other populations has shown promise, this specific investigation into XLA patients and COVID-19 vaccines is relatively novel.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: De Paris, Kristina — Univ of North Carolina Chapel Hill
- Study coordinator: De Paris, Kristina
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.